TOKYO–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and are the first and only percutaneous temporary […]
Other News
Diagnomics Releases Cardiovascular Health Panel on Clinical Microarray Platform
SAN DIEGO, Oct. 7, 2019 /PRNewswire/ — Diagnomics Inc., a San Diego-based genetic testing company, is releasing a cardiovascular-focused genetic report through the Illumina Global Screening Array platform. The new clinical report, Cardiac Care, is now added to the company’s established clinical portfolio, Gene Impetus, that emphasizes medically actionable panels generated from genomic data […]
Accelmed Launches Accelmed Ventures II, a New $100 Million Venture HealthTech Fund
The new fund has already received a commitment from an anchor investor, Vincent Tchenguiz Recent exits of Accelmed’s ventures portfolio companies include the acquisition of Eximo Medical by AngioDynamics for $66 million and Endospan, that entered into an option agreement to be acquired by CryoLife for a total of up […]
Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership
The Company has entered into exclusive negotiations with a leading cardiology laboratory in South America to sign its first regional partnership PARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets […]
Integer Announces Acquisition of US BioDesign Assets
PLANO, Texas, Oct. 07, 2019 (GLOBE NEWSWIRE) — Integer Holdings Corporation (“Integer”) (NYSE:ITGR), a leading medical device outsource manufacturer, today announced it has purchased certain assets of US BioDesign, a manufacturer of complex braided biomedical structures for disposable and implantable medical devices headquartered in Quakertown, Pa. The acquisition will add […]
Canon Medical’s Alphenix ENCORE Plus Program Keeps Customers’ Technology Up-to-Date
Program Provides Latest Interventional Technology While Reducing Cost and Installation Time TUSTIN, Calif.–(BUSINESS WIRE)–In the complex and fast-paced world of health care, customers face the challenge of staying up-to-date with the most advanced systems while also keeping costs down. Providers now have a solution: the Alphenix Encore Plus Program from Canon Medical Systems […]
Blood Flow Monitoring Device – FlowMet-R Gets FDA 510K Clearance
IRVINE, Calif., Oct. 2, 2019 /PRNewswire/ — Laser Associated Sciences (LAS), a medical device company based in Irvine, California, announced that its blood flow monitoring system, FlowMet-R, received its 510(k) clearance from the Food and Drug Administration (FDA). This clearance allows LAS to market and sell the FlowMet-R. The non-invasive portable device addresses a […]
AngioDynamics Acquires Eximo Medical, Ltd. and its Innovative 355nm Laser Atherectomy Technology
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has acquired Eximo Medical, Ltd., an early commercial stage, medical device company, and its proprietary 355nm wavelength laser-technology platform for $46 million in […]
Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced that the first patient has been enrolled in the Phase 3 NODE-303 study. NODE-303 is the Company’s open-label, global safety study of etripamil, […]
Tenaya Therapeutics Closes $92 Million Series B Financing
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2019 /PRNewswire/ — Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver curative therapies that target the underlying causes of heart disease, today announced the successful completion of a $92 million Series B financing. The financing round was led by Casdin Capital and included […]



